The Ministry of Health has launched the use of Lenacapavir, a revolutionary Pre-Exposure Prophylaxis long-acting injectable ...
New Vision on MSN
Uganda launches twice-yearly injectable HIV prevention drug
The twice-yearly HIV injectable drug launch was presided over by the Health Minister and Lira City Woman MP, Dr Jane Ruth Aceng, at Lira Regional Referral Hospital.
Len is a gamechanging drug to prevent HIV infections, priced by Gilead at $28,200. Limited drug is available at cost to ...
Deploying lenacapavir will require rethinking who delivers HIV prevention, how it is financed, and what policy infrastructure ...
Researchers at the Manchester Institute of Biotechnology (MIB) have used engineering biology—an emerging technology that uses ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President’s Emergency ...
Lenacapavir is a long-acting injectable Pre-Exposure Prophylaxis (PrEP) option administered once every six months ...
Uganda on Friday launched the rollout of Lenacapavir, a new long-acting HIV prevention injection, to complement existing HIV prevention methods. Speaking at the national launch in Lira District in ...
The Ministry of Health will, on Friday, roll out the countrywide use of Lenacapavir injection at Lira Regional Referral ...
In a major step forward for South Africa’s HIV response, the government has received the first shipment of a new long-acting ...
This is part of integrated, differentiated and people-centred HIV prevention services, offering new hope for people who face ...
9don MSNOpinion
Hiltzik: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people
Gilead's lenacapavir could transform the fight against HIV — but only if millions more patients can get it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results